185 related articles for article (PubMed ID: 29882448)
1. Genitourinary and gastrointestinal toxicity among patients with localized prostate cancer treated with conventional versus moderately hypofractionated radiation therapy: systematic review and meta-analysis.
Carvalho ÍT; Baccaglini W; Claros OR; Chen FK; Kayano PP; Lemos GC; Weltman E; Kuban DA; Carneiro A
Acta Oncol; 2018 Aug; 57(8):1003-1010. PubMed ID: 29882448
[TBL] [Abstract][Full Text] [Related]
2. Conventional Versus Hypofractionated Radiation Therapy for Localized or Locally Advanced Prostate Cancer: A Systematic Review and Meta-analysis along with Therapeutic Implications.
Datta NR; Stutz E; Rogers S; Bodis S
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):573-589. PubMed ID: 29280452
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
4. Rectal/urinary toxicity after hypofractionated vs. conventional radiotherapy in high risk prostate cancer: systematic review and meta analysis.
Di Franco R; Borzillo V; Ravo V; Ametrano G; Cammarota F; Rossetti S; Romano FJ; D'Aniello C; Cavaliere C; Iovane G; Porricelli MA; Muto M; Berretta M; Facchini G; Muto P
Eur Rev Med Pharmacol Sci; 2017 Aug; 21(16):3563-3575. PubMed ID: 28925488
[TBL] [Abstract][Full Text] [Related]
5. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.
Thor M; Deasy JO; Paulus R; Robert Lee W; Amin MB; Bruner DW; Low DA; Shah AB; Malone SC; Michalski JM; Dayes IS; Seaward SA; Gore EM; Albert M; Pisansky TM; Faria SL; Chen Y; Koontz BF; Swanson GP; Pugh SL; Sandler HM
Radiother Oncol; 2019 Jun; 135():19-24. PubMed ID: 31015166
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy-related toxicity for localized prostate cancer: meta-analysis comparing conventional or moderately hypofractionated vs. ultrahypofractionated protocols.
Baccaglini W; de Carvalho IT; Glina FPA; Pazeto CL; Marantes A; Nascimento M; Farias A; Mendez LC; Tafuri A; Glina S
Clin Transl Oncol; 2022 Jul; 24(7):1425-1439. PubMed ID: 35244866
[TBL] [Abstract][Full Text] [Related]
8. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy.
Sutani S; Ohashi T; Sakayori M; Kaneda T; Yamashita S; Momma T; Hanada T; Shiraishi Y; Fukada J; Oya M; Shigematsu N
Radiother Oncol; 2015 Nov; 117(2):270-6. PubMed ID: 26318662
[TBL] [Abstract][Full Text] [Related]
9. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
11. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
12. Prospective Phase II Trial of Once-weekly Hypofractionated Radiation Therapy for Low-risk Adenocarcinoma of the Prostate: Late Toxicities and Outcomes.
Zimmermann M; Taussky D; Menkarios C; Vigneault É; Beauchemin MC; Bahary JP; Martin AA; Diaz de Bedoya LV; Lambert C
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):386-92. PubMed ID: 26782838
[TBL] [Abstract][Full Text] [Related]
13. High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up.
Hou Z; Li G; Bai S
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1063-71. PubMed ID: 25173623
[TBL] [Abstract][Full Text] [Related]
14. Toxicity after moderately hypofractionated versus conventionally fractionated prostate radiotherapy: A systematic review and meta-analysis of the current literature.
Francolini G; Detti B; Becherini C; Caini S; Ingrosso G; Di Cataldo V; Stocchi G; Salvestrini V; Lancia A; Scartoni D; Giacomelli I; Sardaro A; Carbonara R; Borghesi S; Aristei C; Livi L
Crit Rev Oncol Hematol; 2021 Sep; 165():103432. PubMed ID: 34352361
[TBL] [Abstract][Full Text] [Related]
15. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
16. Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique.
Su AW; Jani AB
Am J Clin Oncol; 2007 Jun; 30(3):215-9. PubMed ID: 17551295
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
[TBL] [Abstract][Full Text] [Related]
18. Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.
Di Franco R; Borzillo V; Ravo V; Ametrano G; Falivene S; Cammarota F; Rossetti S; Romano FJ; D'Aniello C; Cavaliere C; Iovane G; Piscitelli R; Berretta M; Muto P; Facchini G
Oncotarget; 2017 Mar; 8(10):17383-17395. PubMed ID: 28129649
[TBL] [Abstract][Full Text] [Related]
19. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy.
Valdagni R; Italia C; Montanaro P; Lanceni A; Lattuada P; Magnani T; Fiorino C; Nahum A
Radiother Oncol; 2005 Apr; 75(1):74-82. PubMed ID: 15878104
[TBL] [Abstract][Full Text] [Related]
20. Biological-effective versus conventional dose volume histograms correlated with late genitourinary and gastrointestinal toxicity after external beam radiotherapy for prostate cancer: a matched pair analysis.
Jani AB; Hand CM; Pelizzari CA; Roeske JC; Krauz L; Vijayakumar S
BMC Cancer; 2003 May; 3():16. PubMed ID: 12744725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]